Eterna Therapeutics (ERNA) News Today → Dems have chosen Biden replacement? (From Paradigm Press) (Ad) Free ERNA Stock Alerts $1.90 +0.07 (+3.83%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 23, 2024 | americanbankingnews.comEterna Therapeutics (NASDAQ:ERNA) Stock Price Down 5.4%May 10, 2024 | globenewswire.comEterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory DiseasesMay 8, 2024 | globenewswire.comEterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory BoardMay 7, 2024 | finance.yahoo.comEterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory DiseasesMay 7, 2024 | finance.yahoo.comEterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M LocusMarch 27, 2024 | finance.yahoo.comQ4 2023 Cognition Therapeutics Inc Earnings CallMarch 26, 2024 | msn.comViking Therapeutics' experimental tablet helps reduce weight in small studyMarch 15, 2024 | investorplace.comERNA Stock Earnings: Eterna Therapeutics Reported Results for Q4 2023February 23, 2024 | benzinga.comEterna Therapeutics Stock (NASDAQ:ERNA) Dividends: History, Yield and DatesFebruary 20, 2024 | finance.yahoo.comEterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of DirectorsFebruary 20, 2024 | globenewswire.comEterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of DirectorsJanuary 12, 2024 | msn.comEterna Therapeutics files to sell 18.2M shares for holdersJanuary 3, 2024 | finance.yahoo.comEterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)December 21, 2023 | finance.yahoo.comEterna Therapeutics Appoints Sanjeev Luther as President and CEODecember 20, 2023 | msn.comEterna Therapeutics names Sanjeev Luther as CEODecember 20, 2023 | finance.yahoo.comEterna Therapeutics Names Sanjeev Luther as President and Chief Executive OfficerDecember 15, 2023 | msn.comEterna Therapeutics launches convertible debt and warrant financing of up to $9.2MDecember 14, 2023 | finance.yahoo.comEterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant FinancingDecember 6, 2023 | markets.businessinsider.comTreadwell Announces Strategic Pipeline Prioritization and Leadership TransitionsDecember 6, 2023 | marketbeat.comTrading was temporarily halted for "ERNA" at 02:12 PM with a stated reason of "LULD pause."November 1, 2023 | finance.yahoo.comEterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of DirectorsOctober 30, 2023 | markets.businessinsider.comCalidi Biotherapeutics Names Andrew Jackson CFOOctober 30, 2023 | marketwatch.comCalidi Biotherapeutics Names Andrew Jackson Chief Financial OfficerOctober 5, 2023 | markets.businessinsider.comPositive Clinical Outcomes and Continued Genentech Support Bolster Buy Rating for Lineage Cell Therapeutics: An Analysis of OpRegen’s PotentialSeptember 13, 2023 | uk.finance.yahoo.comStem Cell Therapy Contract Manufacturing market is projected to grow at a CAGR of 12.4% by 2033: VisiongainSeptember 8, 2023 | finance.yahoo.comInsider Stock Buying Reaches US$2.7m On Eterna TherapeuticsSeptember 6, 2023 | finance.yahoo.comEterna Therapeutics Teams with Lineage Cell on Transplant TherapiesSeptember 6, 2023 | finance.yahoo.comEterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell TherapeuticsSeptember 5, 2023 | finance.yahoo.comEterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of DirectorsSeptember 5, 2023 | finance.yahoo.comEterna Therapeutics Appoints Dorothy Clarke to Board of DirectorsJuly 18, 2023 | finance.yahoo.comEterna Therapeutics Announces Completion of $8.7 Million of Convertible Debt FinancingJuly 11, 2023 | finance.yahoo.comEterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of DirectorsMay 24, 2023 | finance.yahoo.comEterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General CounselMay 17, 2023 | finance.yahoo.comEterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual MeetingMay 4, 2023 | finance.yahoo.comEterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual MeetingMay 2, 2023 | marketwatch.comEterna Therapeutics Shares Rise 11% After Offer for Exacis Biotherapeutics AssetsMay 2, 2023 | finance.yahoo.comEterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis BiotherapeuticsApril 11, 2023 | marketwatch.comEterna Therapeutics Agrees to $10M Stock Purchase with Lincoln Park CapitalApril 11, 2023 | finance.yahoo.comEterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 MillionMarch 28, 2023 | finance.yahoo.comJeff Karp, Ph.D., Joins Eterna’s Scientific Advisory BoardMarch 24, 2023 | seekingalpha.comERNA Eterna Therapeutics Inc.March 20, 2023 | finance.yahoo.comEterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business HighlightsMarch 16, 2023 | finance.yahoo.comInsiders might want to re-evaluate their US$2.7m stock purchase as Eterna Therapeutics Inc. (NASDAQ:ERNA) drops to US$16mFebruary 3, 2023 | finance.yahoo.comTreadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical OfficerJanuary 26, 2023 | msn.comEterna Therapeutics chief medical officer to resignJanuary 5, 2023 | marketwatch.comEterna Therapeutics Names Matt Angel as Permanent President, CEO >ERNAJanuary 4, 2023 | msn.comEterna appoints Matt Angel as CEO, PresidentJanuary 4, 2023 | finance.yahoo.comEterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and PresidentDecember 20, 2022 | finance.yahoo.comIn a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Dr. Matt Angel, CEO Eterna TherapeuticsDecember 9, 2022 | msn.comWhat's Going On With Eterna Therapeutics Stock Today? Get Eterna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ERNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Gift Could Unleash $51 Billion in New Wealth (Ad)In January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”. You just have to make this simple move before July 30, 2024. ERNA Media Mentions By Week ERNA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ERNA News Sentiment▼0.430.76▲Average Medical News Sentiment ERNA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ERNA Articles This Week▼20▲ERNA Articles Average Week Get Eterna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ERNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: IMRX News NRXP News XLO News ACXP News RVPH News LPCN News VYNE News FBIO News CARA News PMN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ERNA) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eterna Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
